Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Table 2 Postoperative complications in patients
| SR group (n = 148), n (%) | NSR group (n = 161), n (%) | P value | |
| Pulmonary infection | 3 (2.0) | 6 (3.8) | 0.583 |
| Anastomotic fistula | 6 (4.0) | 6 (3.8) | 0.882 |
| Postoperative bleeding | 1 (0.7) | 3 (1.9) | 0.675 |
| Abdominal infection | 3 (2.0) | 9 (5.6) | 0.105 |
| Intestinal obstruction | 3 (2.0) | 1 (0.6) | 0.556 |
- Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589